Detalhe da pesquisa
1.
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 402(10411): 1423-1433, 2023 10 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37633306
2.
Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.
Oncologist
; 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38748596
3.
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
N Engl J Med
; 382(20): 1894-1905, 2020 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32402160
4.
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
J Hepatol
; 76(4): 862-873, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34902530
5.
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(7): 991-1001, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34051880
6.
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lancet Oncol
; 21(6): 808-820, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32502443
7.
The association between malnutrition and the incidence of malaria among young HIV-infected and -uninfected Ugandan children: a prospective study.
Malar J
; 11: 90, 2012 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-22453048
8.
Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma.
J Hepatocell Carcinoma
; 9: 1065-1079, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36254201
9.
Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial.
Liver Cancer
; 11(6): 558-571, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36589722
10.
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
J Clin Oncol
; 40(29): 3365-3376, 2022 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36027558
11.
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.
Nat Med
; 28(8): 1599-1611, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35739268
12.
Effect of nutritional status on response to treatment with artemisinin-based combination therapy in young Ugandan children with malaria.
Antimicrob Agents Chemother
; 55(6): 2629-35, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21383095
13.
Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
Cancer Med
; 10(16): 5437-5447, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34189869
14.
IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.
Ther Adv Med Oncol
; 13: 17588359211036544, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34377158
15.
The effect of varying analytical methods on estimates of anti-malarial clinical efficacy.
Malar J
; 8: 77, 2009 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-19386088
16.
Association between arsenic exposure from drinking water and plasma levels of soluble cell adhesion molecules.
Environ Health Perspect
; 115(10): 1415-20, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17938729
17.
Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions.
Toxicol Lett
; 169(2): 162-76, 2007 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-17293063
18.
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.
J Clin Oncol
; 35(3): 343-351, 2017 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27918718
19.
A randomized, double-blind placebo-controlled trial evaluating the effects of vitamin E and selenium on arsenic-induced skin lesions in Bangladesh.
J Occup Environ Med
; 47(10): 1026-35, 2005 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-16217243
20.
Effect of selenium and vitamin e supplementation on plasma protein carbonyl levels in patients with arsenic-related skin lesions.
Nutr Cancer
; 60(1): 55-60, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18444136